References
- Elia L, Aurisicchio L, Facciabene A et al. CD4(+)CD25(+) regulatory T-cell inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther. DOI: 10.1038/sj.cgt.7701004 (2006) (Epub ahead of print).
- Viehl CT, Moore TT, Liyanage UK et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol.13(9), 1252–1258 (2006).
- Nagai H, Horikawa T, Hara I et al.In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol.13(10), 613–620 (2004).
- Wei WZ, Jacob JB, Zielinski JF et al. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res.65(18), 8471–8478 (2005).
- Facciabene A, Aurisicchio L, Elia L et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum. Gene Ther.17(1), 81–92 (2006).
- Mennuni C, Calvaruso F, Facciabene A et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer117(3), 444–455 (2005).
- Kohm AP, Miller SD. Response to comment on "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells". J. Immunol.177(4), 2037–2038 (2006).
- Kohm AP, McMahon JS, Podojil JR et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol.176(6), 3301–3305 (2006).
- Stephens LA, Anderton SM. Comment on “Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells”. J. Immunol.177(4), 2036; author reply 2037–2038 (2006).
- Zelenay S, Demengeot J. Comment on “Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells”. J. Immunol.177(4), 2036–2037; author reply 2037–2038 (2006).
- Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM. Regulating the immune response to tumours. Adv. Drug Deliv. Rev.58(8), 948–961 (2006).
- Motoyoshi Y, Kaminoda K, Saitoh O et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Reports16(1), 141–146 (2006).
- Li B, Lalani AS, Harding TC et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res.12(22), 6808–6816 (2006).
- Knutson KL, Dang Y, Lu H et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol.177(1), 84–91 (2006).
- Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115(12), 3623–3633 (2005).
- Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).